What was the result of the THALES trial regarding ticagrelor plus aspirin compared to aspirin alone?
The THALES trial showed that ticagrelor plus aspirin was slightly superior to aspirin alone in preventing recurrent stroke (recurrent stroke rate, 5% versus 6.3%; P=0.004) but was also associated with significantly increased risk of severe bleeding (0.5% versus 0.1%; P=0.01).